Accelerate Diagnostics, Inc. (AXDX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.1200 |
| Open | 2.4000 |
| Bid | 2.6100 x 1200 |
| Ask | 2.6800 x 3000 |
| Day's Range | 2.3100 - 2.7300 |
| 52 Week Range | 0.5000 - 7.1900 |
| Volume | |
| Avg. Volume | 1,053,287 |
| Market Cap | 186.701M |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2410 |
| Earnings Date | Feb 21, 2022 - Feb 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.00 |
- Benzinga
Why Accelerate Diagnostics Shares Are Trading Higher Today
Becton Dickinson and Co (NYSE: BDX) will sell Accelerate Diagnostics Inc's (NASDAQ: AXDX) rapid testing solution for antibiotic resistance and susceptibility, offering results in hours versus one to two days with some traditional laboratory methods. Becton Dickinson will market and sell the Accelerate Pheno system and Accelerate Arc module and associated test kits through its global sales network. These solutions complement BD's existing Clinical Microbiology portfolio. The Accelerate PhenoTest
- PR Newswire
Accelerate Diagnostics Reports Second Quarter 2022 Financial Results
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2022.
- PR Newswire
BD, Accelerate Diagnostics Announce Global Commercial Collaboration
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in-vitro diagnostics in microbiology, today announced a worldwide commercial collaboration agreement where BD will offer Accelerate's rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.
